*Correspondence: Juan Huang, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
This change is intended to help address the increased utilization of these medications by reducing off-label use for weight loss
designed a Pt ()-based responsive nanoreactor modified by Cu 2+ -based MOF (termed CuMOF@Pt ()) for enhanced chemotherapy via depleting GSH (Xiang et al., 2021)
A new large-scale study from Truveta and collaborators from Providence, Johns Hopkins, Duke University, and more suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs)semaglutide and tirzepatidemay have another powerful benefit: reducing alcohol-related hospitalizations in people with alcohol use disorder (AUD)
This includes discussing lifestyle modifications, monitoring blood pressure, and addressing any concerns or misconceptions that patients may have
I feel in control and excited for the future